INTEGRA LIFESCIENCES HOLDINGS CORP Q4 FY2024 earnings call

Mojdeh Poul thanked employees for their dedication and introduced herself with her background in the med tech industry. She highlighted Integra's mission, committed workforce, differentiated product portfolio, and leadership position. She discussed operational challenges such as quality, manufacturing, and supply chain issues and the execution of the compliance master plan with 10 work streams. The company is investing in facility equipment upgrades, advancing product strategies for SurgiMend and DuraSorb, expanding internationally, and strengthening leadership roles. The focus is on operational excellence, core growth, and driving innovation for new products.

In the CSS segment, fourth quarter revenues were $314.7 million, representing a 15.8% reported growth and 4.1% organic growth from the prior year. The outsize reported growth was driven by the Acclarent acquisition. Global sales in neurosurgery grew 5.1% organically. The Tissue Technologies segment grew 2% both on a reported and organic basis compared to the prior year. Fourth quarter sales in the Wound Reconstruction franchise increased by 8.2%, driven by double-digit growth in DuraSorb, the UBM portfolio, and AmnioExcel. Private label sales were down 16% versus last year due to component supply delays, and international sales in Tissue Technologies were down low double digits due to longer inventory recovery timelines on Integra Skin.

First quarter 2025 revenues are forecasted to be between $375 million and $385 million, with reported growth in the range of approximately 1.6% to 4.4% and organic growth expected in the range of approximately negative 6.2% to negative 3.5%. For 2025 full year, revenues are projected to be between $1.65 billion and $1.72 billion. Adjusted EPS for the first quarter is expected to be in the range of $0.40 to $0.45. For the full year, adjusted EPS is anticipated to be between $2.41 and $2.51. The guidance reflects supply challenges, investments in the compliance master plan, and potential supply disruptions from the execution of the compliance master plan.

Potential supply disruptions due to the ongoing execution of the compliance master plan, including possible additional shipping holds. Private label component supply delays and variability in Integra Skin production resulting from maintenance schedules and safety stock levels.

Q: Matt Taylor asked about the risk of further ship holds and how derisked the guidance is.

A: Lea Knight stated the guidance includes assumptions for potential shipping holds with $60M at the high end, $90M at the midpoint, and $120M at the low end. Mojdeh Poul discussed Integra Skin production constraints in Q1 but expected improvement in Q2 and beyond.

Q: Vik Chopra inquired about key strategic initiatives and the LRP update.

A: Mojdeh Poul mentioned operational excellence, core growth, and new product innovation as priorities, and stated that the LRP update would take most of 2025 due to assessment.

Q: Robbie Marcus asked about the rationale for future ship holds and cash flow conversion.

A: Lea Knight said the compliance master plan assessment drives consideration of potential disruptions, and free cash flow conversion is expected to improve in 2025 with lower integration costs.

Q: Ryan Zimmerman asked about Acclarent's contribution and P&L margins.

A: Lea Knight said Acclarent is expected to have high single-digit growth in 2025, and the 70 basis point margin decline includes shipping holds and remediation efforts.

Q: Richard Newitter asked about M&A and private label supply.

A: Mojdeh Poul said M&A is part of the growth strategy but the focus is on compliance and capacity, and private label component delay is expected to be resolved in the second half of 2025.

Q: Steven Lichtman asked about private label supply and Integra Skin demand.

A: Lea Knight said private label is expected to return to mid-single digit growth post second half, and Mojdeh Poul emphasized the high demand for Integra Skin.

Q: Craig Bijou asked about Integra Skin production and Acclarent growth.

A: Mojdeh Poul discussed Integra Skin maintenance and capacity projects, and Lea Knight said Acclarent integration went well with expected high single-digit growth in 2025.

Q: Joanne Wuensch asked about private label recovery and revenue cadence.

A: Lea Knight discussed revenue cadence with Q1 headwinds and Q2-Q4 improvement, and private label is expected to return to growth post component delay resolution.

Q: Jayson Bedford asked about private label component impact and Braintree timeline.

A: Lea Knight said the private label component delay impact was on the order of $5M, and Braintree is on track for the first half of 2026.